Acute Heart Failure Syndrome, Dyspnea, Pulmonary Congestion
Conditions
Brief summary
The purpose of this study is to determine if IMED-4 recordings have sufficient precision to detect a clinically significant change in lung fluid status in acute heart failure syndrome with pulmonary congestion.
Detailed description
The study will evaluate if the IMED-4 system has the precision to detect a clinically significant change in lung fluid status for patients with confirmed acute heart failure syndrome with pulmonary congestion. Changes in lung fluid in acute heart failure syndrome are difficult to diagnose and evaluate.
Interventions
DEVICEIMED-4
Non invasive recording electrode used to assess lung fluid
Sponsors
Intersection Medical, Inc.
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Diagnosed with acute heart failure syndrome with pulmonary congestion defined by a Brain natriuretic peptide (BNP) \>350 pg/mL or N-terminal pro-brain natriuretic peptide (NT-pro BNP) \>1500 pg/mL and any one of the following: 1. PCWP \>25mmHg 2. Dyspnea at rest in a recumbent sitting position (30 to 45 degrees), which has worsened within the past week 3. Radiological evidence of CHF on a chest X-ray 4. Physical exam as evidence for pulmonary congestion: i. Presence of an S3 heart sound ii. Lung rales/crackles/crepitations 2. Age greater than or equal to (≥) 18 3. Ability to reliably carry out self-assessment of symptoms 4. Willingness, ability and commitment to participate in index and follow-up IMED-4 recordings
Exclusion criteria
1. Known active myocarditis, obstructive hypertrophic cardiomyopathy, constrictive pericarditis, uncorrected clinically significant primary valvular disease 2. Clinical diagnosis of acute coronary syndrome meeting any 2 of the following 3 criteria: 1. Prolonged chest pain at rest, or an accelerated pattern of angina 2. Electrocardiogram changes indicative of ischemia or myocardial injury 3. Serum troponin \>3 times upper limit of lab normal 3. Clinically-suspected acute mechanical cause of ADHF (e.g., papillary muscular rupture); the diagnosis need not be confirmed by imaging or cardiac catheterization 4. Estimated Glomerular Filtration Rate: eGFR \<30mL/min/1.73m 5. Known vasculitis, active infective endocarditis, or suspected infections including pneumonia, acute hepatitis, systemic inflammatory response syndrome, or sepsis 6. Body temperature ≥38°C just prior to enrollment 7. Acute or chronic respiratory disorder (e.g. severe chronic obstructive pulmonary disease (COPD)) or primary pulmonary hypertension sufficient to cause dyspnea at rest, which may interfere with the ability to interpret dyspnea assessments or hemodynamic measurements 8. Total Albumin \<2.5 g/dL 9. Patients requiring mechanical circulatory support 10. Pregnancy or lactation 11. Patients who have tattoos and/or non-intact skin directly under the electrode sensor position 12. Patients who have had past allergic reactions to medical grade adhesives 13. Patients who have had a lung lobectomy 14. Patients who decline to have their backs photographed with the IMED-4 device in position 15. Severe co-morbidity or poor general physical/mental health that, in the opinion of the Investigator, will not allow the subject to be a good study candidate (i.e. other disease processes, mental capacity, substance abuse, incarceration, shortened life expectance, etc.)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Lung Fluid Status | Up to 1 year | IMED 4 is a new device to measure lung fluid status by assessing how wet or dry the lungs are |
Countries
United States
Outcome results
None listed